MoneyWorks4Me

Lupin informs about press release

24 Dec 2018 Evaluate

Lupin has informed about submission of a Press Release as regards AbbVie Inc. having licensed the company’s MALTI (Mucosa Associated Lymphoid Tissue Lymphoma Translocation Protein I) inhibitor program through which AbbVie gains exclusive global rights to develop and commercialize the company’s MALTI inhibitors. This disclosure is under pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..